← board
RZLT
Rezolutedistress 2/10 · well-funded / low risk$4.97-1%today-55% from 52w high
Lead: congenital hyperinsulinism
Revenue
pre-revenue
Liquidity
$120M
Runway
1.4 yrs
Shares 1y
+6%
Price & events
+52.0% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.6%
1D
+13.7%
1W
+1.6%
1M
+59.8%
3M
+41.2%
6M
-15.5%
1Y
+6.4%
2Y
-51.1%
5Y
-61.0%
All
Overview
- Market Cap
- $478.57M
- Volume
- 58.81K
- 52 Week Range
- $1.40 – $10.94
- Total Shares
- 96.29M
- Float Shares
- 66.01M
- Short %
- 25.65%
- % Held by Insiders
- 10.15%
- % Held by Institutions
- 90.58%
- RVOL
- 0.03x
- Beta
- 0.55
Pipeline stages · 1 programs
RZ358 (5 mg/kg) + SOC (Standard-of-Care) or Placebo + SOC, RZ358 (10 mg/kg) or Placebo + SOC, RZ358 (5-10 mg/kg) + SOC
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2025-11-14 | Phase 3 | RZ358 (5 mg/kg) + SOC (Standard-of-Care) or Placebo + SOC, RZ358 (10 mg/kg) or Placebo + SOC, RZ358 (5-10 mg/kg) + SOC | Congenital Hyperinsulinism | 56 | active not recruiting |
Catalyst news & presentations · 13
- second half of 2026Guided 55%readoutPhase 3ersodetug · Topline results from Phase 3 upLIFT study in tumor HISEC 8-K
- 2026-09-16earningsEarningsEarnings releaseyahoo
- second half of 2026readoutPhase 3ersodetug · Topline data from upLIFT trialSEC 8-K
- 2026-03-17fda agreementersodetug · FDA encouraged submission of study reports and datasets for independent evaluation.SEC 8-K
- second half of 2025readoutPhase 3RZ358 · Announce topline data from Phase 3 sunRIZE studySEC 8-K
- December 2025readoutPhase 3ersodetug · Topline data anticipated in December 2025.SEC 8-K
- 2025-08-19fda agreementersodetug · FDA agreed to modify upLIFT trial to single-arm open-label with as few as 16 patientsSEC 8-K
- Q2 2025enrollment completesecondaryPhase 3ersodetug · Enrollment completion expected, subject to IA outcomeSEC 8-K
- mid-2025readoutPhase 3RZ358 (ersodetug) · Topline data from ongoing global pivotal Phase 3 trialSEC 8-K
- first half of 2025trial initiationsecondaryPhase 3RZ358 (ersodetug) · Patient enrollment start for Phase 3 registrational studySEC 8-K
- early 2025trial initiationsecondaryPhase 3RZ358 · Commence U.S. enrollment in ongoing Phase 3 sunRIZE studySEC 8-K
- 2024-09-09fda agreementRZ358 · FDA completely removed partial clinical holds on RZ358 for congenital hyperinsulinismSEC 8-K
- 2024-08-05fda agreementRZ358 (ersodetug) · FDA clearance of IND application for Phase 3 study in tumor hyperinsulinismSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $8 (+54% upside) · 9 analysts
- 2026-06-15GuggenheimBuy
- 2026-06-03CitizensMarket Perform → Market Outperform
- 2026-06-03Maxim GroupBuy
- 2026-06-03WedbushOutperform
- 2026-06-02HC Wainwright & Co.Buy
- 2026-06-02BTIGBuy
Competitors — congenital hyperinsulinism
- none identified
Recent news
- 2026-07-21Rezolute Management to Meet Investors Online July 28-29 - Stock Titan
- 2026-07-21Rezolute to Participate in the BTIG Virtual Biotechnology Conference - Hastings Tribune
- 2026-07-21Rezolute to Participate in the BTIG Virtual Biotechnology Conference - GlobeNewswire
- 2026-07-21Rezolute to Participate in the BTIG Virtual Biotechnology Conference - Yahoo Finance
- 2026-07-21Rezolute to Participate in the BTIG Virtual Biotechnology Conference - GlobeNewswire
- 2026-07-21Revenue extends RZLT filing deadline - Irish Farmers Journal
- 2026-07-20RZLT deadline approaching at the end of March - Irish Farmers Journal
- 2026-07-19Opinion: RZLT as dangerous for Government as it is for farmers with zoned land - Irish Farmers Journal
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.